• 5296 Citations
  • 36 h-Index
1993 …2019

Research output per year

If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Do Sik Min is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 9 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output

  • 5296 Citations
  • 36 h-Index
  • 192 Article
  • 2 Review article
  • 1 Short survey

A Ras destabilizer KYA1797K overcomes the resistance of EGFR tyrosine kinase inhibitor in KRAS-mutated non-small cell lung cancer

Park, J., Cho, Y. H., Shin, W. J., Lee, S. K., Lee, J. H., Kim, T., Cha, P. H., Yang, J. S., Cho, J., Min, D. S., Han, G., Lee, H. Y. & Choi, K. Y., 2019 Dec 1, In : Scientific reports. 9, 1, 648.

Research output: Contribution to journalArticle

  • 7 Citations (Scopus)

    A therapeutic strategy for chemotherapy-resistant gastric cancer via destabilization of both β-catenin and ras

    Ryu, W. J., Lee, J. E., Cho, Y. H., Lee, G., Seo, M. K., Lee, S. K., Hwang, J. H., Min, D. S., Noh, S. H., Paik, S., Kim, S., Cheong, J. H. & Choi, K. Y., 2019 Apr, In : Cancers. 11, 4, 496.

    Research output: Contribution to journalArticle

    Open Access
  • 3 Citations (Scopus)

    WDR76 degrades RAS and suppresses cancer stem cell activation in colorectal cancer

    Ro, E. J., Cho, Y. H., Jeong, W. J., Park, J. C., Min, D. S. & Choi, K. Y., 2019 Jul 30, In : Cell Communication and Signaling. 17, 1, 88.

    Research output: Contribution to journalArticle

    Open Access
  • 3 Citations (Scopus)

    WDR76 is a RAS binding protein that functions as a tumor suppressor via RAS degradation

    Jeong, W. J., Park, J. C., Kim, W. S., Ro, E. J., Jeon, S. H., Lee, S. K., Park, Y. N., Min, D. S. & Choi, K. Y., 2019 Dec 1, In : Nature communications. 10, 1, 295.

    Research output: Contribution to journalArticle

  • 7 Citations (Scopus)

    A small molecule approach to degrade RAS with EGFR repression is a potential therapy for KRAS mutation-driven colorectal cancer resistance to cetuximab

    Lee, S. K., Cho, Y. H., Cha, P. H., Yoon, J. S., Ro, E. J., Jeong, W. J., Park, J., Kim, H., Il Kim, T., Min, D. S., Han, G. & Choi, K. Y., 2018 Nov 1, In : Experimental and Molecular Medicine. 50, 11, 153.

    Research output: Contribution to journalArticle

  • 3 Citations (Scopus)